Tiziana’s therapeutic focus is on the treatment of inflammatory, autoimmune diseases and oncology.
Oral Foralumab dosing can be used to treat Crohn’s disease while nasally administered Foralumab can be used for treatment of progressive multiple sclerosis and other autoimmune disease indications. The Company will be shortly initiating phase 2 studies with a patented formulation for oral administration of foralumab for Crohn's Disease indication and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This compound has potential applications in a wide range of autoimmune and inflammatory diseases where modulation of a T-cell response is desirable.
Anti-IL-6R monoclonal antibody can be used alone or in combination with other antiviral drugs such as remdesivir through inhalation administration as a possible treatment of COVID-19.
Milciclib is being evaluated for treatment of hepatocellular carcinoma (HCC) either as monotherapy or in combination with tyrosine kinase inhibitors such as regorafenib and sorafenib. Results from the Phase 2 monotherapy trial were reported at the 2020 Virtual ASCO Meeting. Milciclib is also being used for treatment of recurrent HCC in liver transplant patients in an investigator-initiated clinical trial, as reported in an abstract at the 2020 Virtual ASCO Meeting. Tiziana intends to conduct a larger trial in liver transplant patients with recurrent HCC using this drug combination.
Our product pipeline also includes StemPrintER™, a multi-gene signature prognostic assay to identify patients at high risk for breast cancer. StemPrintER shows superiority to Oncotype Dx in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients. On May 29, 2020 Tiziana announced the spin out of StemPrintER and SPARE (together "StemPrintER") into a separate company.